目的：为提升药械组合产品属性界定的申请资料质量、提高属性界定工作效率提出建议。方法： 对比分析中美2009年至2019年属性界定申请现状和监管政策、分析我国属性界定工作存在的问题。结果与结论：对于药械组合产品属性界定的受理、审查和复审环节容易出现的问题提出解决对策。借鉴美国 FDA管理经验，提出提升我国药械组合属性界定工作质量和效率的建议。
Abstract
Objective: To put forward several suggestions for improving the quality of application materials and the efficiency of attribute definition of drug-device combination products. Methods: The present situation and regulatory policies of application for attribute definition in China and the United States from 2009 to 2019 were contrastively analyzed, and the problems existing in attribute definition work in China were analyzed. Results and Conclusion: Relevant countermeasures for common problems in the process of acceptance, examination and review of the definition of the attributes of the combination products were proposed. Based on the management experience of FDA, some suggestions were put forward to improve the quality and efficiency of the definition of pharmaceutical device combination attribute definition in China.
关键词
药械组合产品；属性界定；申报流程；申请资料；监管对策
{{custom_keyword}} /
Key words
drug-device combination products； attribute definition； submission procedure； application materials； supervision countermeasures
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 母瑞红.组合医疗产品分类管理现状与思考[J].中国医疗器械信息,2019,25(9):10-11,141.
[2] 王永清,许伟,田佳鑫.药械组合产品申报常见问题的思考[J].中国医疗器械信息,2019,25(19):12-13,83.
[3] 田佳鑫,许耘,杨晓冬,等.药械组合产品属性界定常见问题的思考[J].中国医疗器械杂志,2019,43(2):126-128.
[4] 田佳鑫,杨晓冬,邓洁.我国药械组合产品的申报流程、基本情况介绍及器械部分申报资料要求[J].中国医疗器械信息,2016,22(19):24-27.
[5] 田佳鑫,王永清,许伟,等.药械组合产品申报资料常见问题分析[J].中国医疗器械杂志,2020,44(1):68-70.
[6] 国家食品药品监督管理局.关于药械组合产品注册有关事宜的通告(2009年第16号)[EB/OL].(2009-11-12)[2021-04-09].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20091112141901388.html.
[7] 国家药品监督管理局.关于调整药械组合产品属性界定有关事项的通告(2019年第28号)[EB/OL].(2019-05-31)[2021-04-09].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20190531180601758.html.
[8] 牟岚,杜新.美国FDA对医疗组合产品的监管[J].药学进展,2019,43(12):892-899.
[9] FDA.FY 2019 Performance Report to Congress for the Office of Combination Products[EB/OL].(2020-08)[2021-04-09].https://www.fda.gov/about-fda/reports/combination-products-performance-reports.
[10] FDA.Guidance for Industry:How to Write a Request for Designation(RFD)[EB/OL].(2011-04)[2021-04-09].https://www.fda.gov/regulatory-information/search-fdaguidance-documents/how-write-request-designation-rfd.
[11] FDA.Guidance for Industry:How to Prepare a Pre-Request for Designation(Pre-RFD)[EB/OL].(2018-02)[2021-04-09].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-prepare-prerequest-designation-pre-rfd.
[12] FDA.Guidance for Industry and FDA Staff:Classification of Products as Drugs and Devices & Additional Product Classification Issues[EB/OL].(2017-09)[2021-04-09].https://www.fda.gov/regulatory-information/search-fdaguidance-documents/classification-products-drugs-anddevices-and-additional-product-classification-issues.
[13] FDA.Early Development Considerations for Innovative Combination Products[EB/OL].(2006-09)[2021-04-09].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-developmentconsiderations-innovative-combination-products.
[14] 李新英,董江萍.美国FDA组合式医药产品监管现状简析[J].中国新药杂志,2019,28(22):2681-2686.
[15] 高京,孙强,宋英杰.药械组合产品上市后质量安全监管的国际经验探讨[J].中国药物评价,2020,37(3):178-180.
[16] 欧洲医药评价局.Guideline on the quality requirements for drug-device combinations[EB/OL].(2019-05-29)[2021-04-09].https://www.ema.europa.eu/en/qualityrequirements-drug-device-combinations.
[17] 国家食品药品监管总局.总局关于发布医疗器械分类目录的公告(2017年第104号)[EB/OL].(2017-09-04)[2021-04-09].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20170904150301406.html.
[18] 国家药监局医疗器械标准管理中心.2017年至2019年 7月已发布药械组合产品属性界定结果汇总[EB/OL].(2019-07-24)[2021-04-09].https://www.nifdc.org.cn/nifdc/bshff/ylqxbzhgl/qxxxgk/yxzh/20190724105922361.html.
[19] 国家食品药品监督管理局.关于医用透明质酸钠产品管理类别的公告(2009年第81号)[EB/OL].(2009-12-24)[2021-04-09].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20091112141901388.html.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
中国食品药品检定研究院2020年度中青年发展研究基金(编号 2020G2)
{{custom_fund}}
